Alpha-GPC Explained: Brain Chemistry, Memory, and Cognitive Function
BioAdaptives Editorial Team
What Alpha-GPC does in the brain, what human research reveals about cognitive performance, and what to consider before choosing a supplement.
You've probably seen Alpha-GPC listed in supplements marketed for memory, focus, and mental clarity. The explanation often sounds convincing: Alpha-GPC provides choline, the brain uses choline to produce acetylcholine, and acetylcholine helps support learning and memory.
But does taking Alpha-GPC actually make you think more clearly?
Alpha-GPC is a choline-containing compound involved in normal brain chemistry. It provides a source of choline, an essential nutrient needed to produce acetylcholine, a neurotransmitter involved in attention, learning, and memory.
Human studies have reported encouraging cognitive results in people with Alzheimer's dementia and mild cognitive impairment. However, there is not enough consistent evidence to conclude that Alpha-GPC reliably improves memory, concentration, or everyday mental performance in healthy adults.
That distinction matters when evaluating alpha GPC cognitive function claims. Understanding how an ingredient works is important, but knowing whether it produces meaningful results in people is what makes the research useful.
What Is Alpha-GPC?
Alpha-GPC, short for L-alpha-glycerylphosphorylcholine, is a choline-containing compound also known as choline alphoscerate.
It is associated with phospholipid metabolism and serves as a source of choline, an essential nutrient used throughout the body.
Choline has several established physiological functions:
- Neurotransmitter production: It is required to synthesize acetylcholine, which participates in attention, memory, learning, and muscle activation.
- Cell-membrane structure: It contributes to phosphatidylcholine and other compounds essential for maintaining cellular membranes.
- Metabolic regulation: It participates in methyl-group metabolism, which supports numerous biochemical reactions.
These functions are described in the National Institutes of Health's Choline Fact Sheet.
Alpha-GPC has attracted scientific interest because of its relationship to these pathways, particularly those involved in neurological function.
Researchers have investigated it in people experiencing cognitive impairment. Supplement manufacturers have also incorporated it into products intended for cognitive wellness.
Those uses are related, but the evidence supporting them is not identical.
Why Is Alpha-GPC Considered a Nootropic?
Alpha-GPC is commonly described as a nootropic ingredient.
Nootropic is a broad term for substances investigated or marketed for their potential effects on cognition, including memory, attention, and learning.
The term does not indicate a particular mechanism or guarantee effectiveness.
Some nootropic ingredients have been investigated extensively in humans. Others are supported mainly by preliminary experiments or theoretical mechanisms.
Alpha-GPC occupies an interesting position: its connection to choline metabolism is well established, while its effectiveness for general cognitive enhancement remains less certain.
For more background on this distinction, see BioAdaptives' guide to nootropics and cognitive support supplements.
How Does Alpha-GPC Work in the Brain?
Alpha-GPC's scientific relevance begins with choline.
The body uses choline in several metabolic pathways, including those involved in neurotransmitter synthesis and cellular structure.
Understanding these pathways helps explain why researchers study Alpha-GPC—and why its biological role should not be confused with proven cognitive benefits.
Choline and Acetylcholine: The Brain Chemistry Connection
Acetylcholine is a neurotransmitter, a chemical messenger that helps nerve cells communicate.
It participates in neural circuits involved in attention, learning, memory, and other functions.
Specialized nerve cells called cholinergic neurons produce acetylcholine by combining choline with acetyl-CoA.
An enzyme called choline acetyltransferase facilitates the reaction:
Choline + Acetyl-CoA → Acetylcholine
After synthesis, acetylcholine is packaged into small structures called synaptic vesicles.
When a cholinergic neuron becomes active, acetylcholine can be released into the space between cells, where it interacts with receptors and helps transmit a signal.
An enzyme called acetylcholinesterase subsequently breaks it down. Choline can then be transported back into nerve cells for reuse.
This process allows the nervous system to regulate communication with considerable precision.
Because acetylcholine participates in memory and attention, compounds that influence choline availability have become subjects of cognitive research.
But acetylcholine production is only one part of a much larger system.
Does More Choline Mean More Acetylcholine?
Not necessarily.
Imagine a factory that needs raw materials, specialized equipment, and coordinated production schedules.
Supplying additional raw material may help when a shortage limits production. But adding more material does not automatically increase output if production is regulated by other factors.
The brain operates under similar constraints.
Acetylcholine signaling depends on choline availability, transport into neurons, enzyme activity, neuronal demand, receptor function, and neurotransmitter recycling.
Increasing choline intake does not guarantee that acetylcholine signaling will increase in a beneficial way.
This creates an important distinction between three statements:
- Alpha-GPC supplies choline.
- Choline is required for acetylcholine synthesis.
- Alpha-GPC supplementation improves memory or concentration.
The first two describe established biochemical relationships.
The third is a clinical claim that must be demonstrated through human research.
A plausible mechanism explains why an ingredient is worth studying. It does not prove that taking the ingredient improves cognitive performance.
Alpha-GPC and Brain-Cell Membranes
Choline also contributes to the production of phosphatidylcholine, an important component of cell membranes.
Neurons depend on specialized membranes to maintain their structure, regulate molecular movement, and support electrical and chemical communication.
Phospholipids help organize membrane proteins and preserve the conditions needed for normal cellular function.
Alpha-GPC's relationship to choline and phospholipid metabolism therefore extends beyond neurotransmitter synthesis.
However, participating in membrane metabolism does not establish that Alpha-GPC supplementation repairs damaged neurons, reverses brain aging, or promotes neurological regeneration.
Those outcomes would require direct evidence from appropriately designed studies.
Choline's Role in Other Metabolic Processes
Choline is also involved in methyl-group metabolism.
Through its conversion to betaine, choline contributes to biochemical reactions that help regulate normal cellular metabolism, including homocysteine-related pathways.
This matters because choline is not used exclusively for acetylcholine production.
The body distributes choline among multiple physiological needs.
As a result, the relationship between Alpha-GPC intake and cognitive performance cannot be reduced to a single chemical reaction.
What Does Human Research Say About Alpha-GPC and Cognitive Function?
Human research has produced encouraging findings, particularly among people with existing cognitive impairment.
However, the studies vary in their participants, treatment periods, outcome measures, and methodological quality.
The most useful approach is to examine what each study actually measured—and what its findings can reasonably tell us.
Alpha-GPC Research in Alzheimer's Dementia
A randomized, double-blind, placebo-controlled trial published in Clinical Therapeutics in 2003 investigated choline alphoscerate in 261 people with mild-to-moderate Alzheimer's dementia.
Participants received either placebo or 400 mg of choline alphoscerate three times daily for 180 days.
Researchers assessed cognition using several instruments, including the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE).
ADAS-Cog measures selected cognitive abilities, including memory and language. Lower scores indicate better performance.
After 180 days:
- The choline alphoscerate group's average ADAS-Cog score improved by 3.20 points from baseline.
- The placebo group's average score worsened by 2.90 points.
- Other cognitive and clinical assessments generally favored the treatment group.
These results suggest that choline alphoscerate may influence certain cognitive outcomes in people with Alzheimer's dementia.
However, several limitations deserve attention.
The participants already had diagnosed dementia. The trial did not investigate healthy adults seeking better concentration or memory.
The study lasted six months, so it did not establish long-term effects on disease progression.
A subsequent systematic review by the Agency for Healthcare Research and Quality rated the trial as having a medium overall risk of bias.
What the study supports: Favorable cognitive assessment results over six months in people with mild-to-moderate Alzheimer's dementia.
What it does not establish: Dementia prevention, reversal of underlying neurodegeneration, or improved cognitive performance in healthy adults.
Sources: 2003 randomized clinical trial and AHRQ evidence review.
Alpha-GPC Research in Mild Cognitive Impairment
A randomized, double-blind, placebo-controlled trial published in BMC Geriatrics in 2024 investigated Alpha-GPC in 100 enrolled participants with amnestic mild cognitive impairment.
Mild cognitive impairment involves measurable cognitive difficulties beyond those typically expected with aging, while everyday independence is generally preserved.
Participants received either 600 mg of Alpha-GPC daily or placebo for 12 weeks.
The primary outcome involved changes in ADAS-Cog scores.
Although 100 participants were enrolled, 74 were included in the reported primary cognitive-outcome analysis.
Researchers found:
| Cognitive outcome | Alpha-GPC group | Placebo group |
|---|---|---|
| Average ADAS-Cog improvement | 2.34 points | 0.97 points |
| Participants in reported analysis | 42 | 32 |
The difference in average improvement was approximately 1.37 points, favoring Alpha-GPC.
The between-group difference reached statistical significance, with a reported p-value of 0.048.
The memory component of ADAS-Cog also showed a statistically significant difference.
Not every assessment produced the same result.
The study did not find a statistically significant between-group difference in total scores on the Korean version of the Montreal Cognitive Assessment.
Nor did it establish a significant advantage in instrumental activities of daily living.
This is an important distinction for readers evaluating cognitive supplement claims.
A measurable change on a cognitive assessment does not automatically demonstrate improved independence, better everyday decision-making, or long-term protection against cognitive decline.
The trial was relatively small, lasted only 12 weeks, and had fewer participants in its primary outcome analysis than originally enrolled.
The research also received funding from Suheung, a company associated with the investigated Alpha-GPC ingredient. Funding does not invalidate a study, but it is relevant when weighing the findings alongside independent research.
No serious adverse events were reported during the study, and adverse-event incidence did not differ significantly between groups.
What the study supports: A modest improvement on a specific cognitive assessment among participants with mild cognitive impairment.
What remains uncertain: Whether the effect persists, produces meaningful daily-life benefits, or applies to otherwise healthy adults.
Source: 2024 randomized clinical trial.
Does Alpha-GPC Improve Focus in Healthy Adults?
This is one of the most common questions among people researching Alpha-GPC supplements.
A healthy professional may want to maintain concentration during demanding work. A student may be interested in learning and information retention. An older adult may want to preserve mental sharpness.
These goals are different from treating diagnosed cognitive impairment.
Research involving healthy adults has explored selected cognitive and performance-related outcomes, but the available evidence does not establish consistent, clinically meaningful improvements in memory, attention, or everyday mental performance.
The distinction between laboratory measurements and real-world benefits is particularly important.
Suppose a study finds that participants respond slightly faster during a computerized task.
That result may be scientifically interesting, but it does not necessarily mean participants will make better decisions, remember more information over time, or perform more effectively at work.
Those outcomes require separate measurements.
For healthy adults, Alpha-GPC remains an ingredient with a plausible biological rationale but insufficient evidence of reliable general cognitive enhancement.
What the Research Actually Establishes
| Research question | Current evidence | Practical interpretation |
|---|---|---|
| Does Alpha-GPC provide choline? | Established biochemistry | Yes |
| Is choline required for acetylcholine production? | Established physiology | Yes |
| Can Alpha-GPC improve certain cognitive scores in Alzheimer's dementia? | Favorable results in an older randomized trial | Promising, but not definitive |
| Can Alpha-GPC improve certain scores in mild cognitive impairment? | Positive results in a 2024 randomized trial | Encouraging, with limited follow-up |
| Does Alpha-GPC reliably improve focus in healthy adults? | Limited and heterogeneous research | Not established |
| Does Alpha-GPC prevent dementia? | Insufficient evidence | Not demonstrated |
| Is long-term supplementation conclusively safe? | Incomplete long-term safety evidence | Uncertain |
The evidence is not simply positive or negative. Its relevance depends on the population studied, the outcome measured, and the quality of the research.
Alpha-GPC vs. Citicoline and Dietary Choline
Alpha-GPC is not the only substance associated with choline metabolism.
Citicoline and ordinary dietary choline are frequently discussed alongside it, but each has a different role in nutritional and cognitive research.
Alpha-GPC vs. Citicoline
Citicoline, also known as CDP-choline, is a compound involved in pathways related to phosphatidylcholine synthesis.
Following administration, citicoline contributes metabolites including choline and cytidine, which is converted to uridine in humans.
Alpha-GPC has a different chemical structure and metabolic profile.
Both compounds have been investigated for neurological applications.
However, differences in their chemistry do not establish that one is universally more effective than the other for memory, attention, or concentration.
Reliable comparisons would require well-designed head-to-head clinical trials involving similar populations and meaningful cognitive outcomes.
Without that evidence, claims of categorical superiority are premature.
Alpha-GPC vs. Choline From Food
Choline is an essential nutrient naturally present in foods such as eggs, meat, poultry, fish, soybeans, and certain legumes.
Meeting normal choline requirements supports established physiological functions.
Supplementing with Alpha-GPC raises a separate question: whether additional intake of a concentrated choline-containing compound provides benefits beyond nutritional adequacy.
| Choline source | Main role or research interest | Important limitation |
|---|---|---|
| Dietary choline | Meeting essential nutritional requirements | Extra intake does not necessarily improve memory |
| Alpha-GPC | Investigated choline-containing compound | Cognitive benefits depend on clinical context |
| Citicoline | Distinct compound associated with phospholipid metabolism | Superiority over Alpha-GPC is not established |
For someone whose diet provides inadequate choline, improving nutritional adequacy has a clear physiological rationale.
For someone already meeting nutritional needs, additional supplementation does not automatically improve cognition.
BioAdaptives explores the broader relationship between nutrition and neurological wellness in foods that support brain health.
Alpha-GPC Safety: What Do We Know?
Understanding potential benefits is only part of evaluating a supplement ingredient.
Long-term safety, individual health circumstances, and the limitations of available research also matter.
What Short-Term Clinical Trials Report
In the 2024 mild cognitive impairment trial, researchers reported no serious adverse events during the 12-week intervention.
Adverse-event incidence did not differ significantly between the Alpha-GPC and placebo groups.
Reported symptoms included gastrointestinal complaints such as nausea, constipation, abdominal discomfort, and indigestion.
These findings provide useful information about short-term tolerability under the study's conditions.
They do not establish that long-term supplementation is risk-free.
A relatively small trial lasting several weeks cannot reliably detect uncommon adverse outcomes or determine what happens after years of use.
The Observational Research on Stroke Risk
A large population-based cohort study published in JAMA Network Open in 2021 investigated whether Alpha-GPC prescription exposure was associated with subsequent stroke.
Researchers analyzed South Korean health records involving 12,008,977 individuals, including 108,877 people with recorded Alpha-GPC use.
The study population consisted of adults aged 50 years or older without recorded underlying stroke, Alzheimer's disease, or cerebrovascular disease at baseline.
Researchers also constructed a matched cohort to improve comparability between exposed and unexposed groups.
In the matched analysis, Alpha-GPC exposure was associated with a higher hazard of stroke.
The reported adjusted hazard ratio was 1.43, with a 95% confidence interval of 1.41–1.46.
A hazard ratio of 1.43 represents an estimated 43% higher relative hazard under the study's statistical model.
It does not mean that 43% of Alpha-GPC users experienced a stroke, nor does it indicate a 43-percentage-point increase in absolute risk.
The researchers also reported an association between longer prescription exposure and higher stroke risk.
These findings raise a meaningful safety question, but they do not prove that Alpha-GPC causes stroke.
The study was observational rather than randomized.
People receiving Alpha-GPC prescriptions may differ from nonusers in underlying health, neurological conditions, healthcare utilization, and other factors.
Statistical adjustments can reduce some differences but cannot eliminate every source of confounding.
The results also concern prescription exposure in a particular healthcare population. They should not automatically be applied to every commercial supplement formulation or pattern of use.
In September 2026, JAMA Network Open published a correction addressing reversed ischemic and hemorrhagic stroke diagnostic-code descriptions in the original Methods section, along with an author-information error.
The correction was not a retraction.
What the research found: An association between Alpha-GPC prescription exposure and subsequent stroke.
What remains unproven: Whether Alpha-GPC itself caused the association or whether the reported risk applies to other populations and supplement-use patterns.
Sources: 2021 cohort study and September 2026 correction.
How Should Readers Interpret the Safety Evidence?
Short-term clinical trials and long-term observational studies provide different kinds of information.
The clinical trials offer evidence about tolerability under controlled conditions.
The observational findings raise questions about possible long-term risks that those trials were not designed to answer.
Neither type of study should be interpreted beyond what it measured.
For someone considering prolonged Alpha-GPC use, especially with neurological or cardiovascular health concerns, these uncertainties are worth discussing with a qualified healthcare professional.
How to Evaluate Alpha-GPC Supplement Claims
The most useful supplement research starts with a clear question: What specific benefit am I looking for, and has that benefit actually been demonstrated?
Five considerations help answer it.
1. Look at Who Was Studied
Research involving people with Alzheimer's dementia or mild cognitive impairment does not automatically apply to healthy adults.
Age, cognitive status, medical history, and nutritional adequacy can affect how relevant a result is.
2. Examine What Researchers Measured
A cognitive test score, reaction-time measurement, self-reported concentration rating, and daily-functioning assessment are not interchangeable.
A statistically significant change on one measure does not establish improvement in every aspect of cognition.
The outcome should match the claimed benefit.
3. Consider the Study Design
Randomized, placebo-controlled trials are generally more informative about intervention effects than uncontrolled studies.
Without an appropriate comparison group, improvements may reflect expectations, repeated testing, natural variation, or other influences.
4. Distinguish Statistical Significance From Practical Benefit
A small difference may be statistically detectable without producing a noticeable improvement in everyday life.
Study duration matters, too.
A result measured after 12 weeks does not establish that the effect will persist for years.
5. Check Whether the Finished Product Was Studied
An ingredient study is not the same as a finished-product study.
A commercial supplement may contain Alpha-GPC alongside other compounds, in different amounts or formulations than those used in clinical trials.
Research involving Alpha-GPC alone does not establish that every supplement containing it produces the same effects.
Likewise, evidence involving a biochemical pathway, biomarker, or technology platform should not be presented as proof that a finished product improves clinical outcomes.
A Practical Example
Consider two people researching Alpha-GPC.
One is a healthy professional interested in improving concentration during long workdays.
The other has mild cognitive impairment and wants to understand published clinical findings.
Both are interested in memory and attention, but the available clinical trials are more directly relevant to the second person's research question.
Even then, the studies do not establish that a particular commercial supplement will reproduce the reported findings.
For the healthy professional, the evidence supporting improved everyday performance is less direct.
The important question is not simply whether Alpha-GPC has been studied.
It is whether the research addresses the specific outcome that matters to the reader.
Alpha-GPC and the Broader Picture of Cognitive Wellness
Brain chemistry is only one part of cognitive health.
Nutrition, sleep, cardiovascular health, physical activity, and other factors influence how the brain functions.
These systems interact rather than operating independently.
Sleep, for example, contributes to memory consolidation and attention.
Someone experiencing poor concentration because of inadequate sleep may not address the underlying issue by adding a choline-containing supplement.
BioAdaptives explores this relationship in its article on sleep and cognitive function.
This broader perspective is reflected in BioAdaptives' Human Renewal Framework, which connects Cellular Wellness, Human Performance, Biological Resilience, Healthy Longevity, and Science-Driven Health Optimization.
Alpha-GPC research is especially relevant to Human Performance because it examines biological pathways involved in cognitive function.
It also illustrates the value of Science-Driven Health Optimization: understanding mechanisms, examining clinical evidence, and recognizing the difference between promising findings and established benefits.
The Connection to MyndSystem™
BioAdaptives identifies MyndSystem™ as part of its broader human-performance and cognitive-wellness platform portfolio.
The company's product documentation describes MyndMed™ as the daytime component and MyndRenew™ as the nighttime component of the system.
The documented MyndSystem™ website now directs visitors to ClearMynd™, a BioAdaptives division presenting MyndMed as a daily cognitive-support product.
This current website presentation is distinct from the broader MyndSystem architecture described in the corporate materials.
Neither the supplied product documentation nor the research reviewed for this article establishes that MyndSystem, MyndMed, or MyndRenew contains Alpha-GPC or produces cognitive benefits attributable to this ingredient.
The relevant connection is the larger wellness perspective: cognitive performance involves daily function, recovery, and interconnected biological systems rather than one isolated compound.
Frequently Asked Questions About Alpha-GPC
Is Alpha-GPC the Same as Choline?
No. Alpha-GPC is a compound containing choline. Choline is an essential nutrient involved in neurotransmitter production, cell-membrane structure, and metabolic processes. Alpha-GPC can contribute to choline availability, but the terms are not interchangeable.
Does Alpha-GPC Increase Acetylcholine?
Alpha-GPC provides choline that can participate in acetylcholine synthesis. However, this does not establish that supplementation consistently increases acetylcholine signaling in the human brain or improves cognitive performance. Neurotransmitter activity is regulated by several biological processes.
Does Alpha-GPC Cross the Blood-Brain Barrier?
Alpha-GPC is investigated as a source of choline relevant to nervous-system metabolism. However, claims about how much intact Alpha-GPC crosses the human blood-brain barrier, or how supplementation changes brain acetylcholine levels, require specific pharmacokinetic evidence. Those mechanisms should not be assumed to establish cognitive benefits.
Can Alpha-GPC Improve Memory and Focus?
Some randomized trials have reported favorable cognitive assessment results in people with Alzheimer's dementia or mild cognitive impairment. Evidence that Alpha-GPC reliably improves memory, focus, or everyday mental performance in healthy adults remains limited.
Is Alpha-GPC Better Than Citicoline?
Current evidence does not establish that Alpha-GPC is universally superior to citicoline for cognitive function. The compounds differ chemically, and meaningful comparisons require direct clinical research involving similar populations and outcomes.
What Alpha-GPC Dosages Have Been Studied?
The 2003 Alzheimer's dementia trial used 400 mg three times daily. The 2024 mild cognitive impairment trial used 600 mg daily.
These amounts describe specific research interventions. They are not established dosing recommendations for healthy adults or proof that those amounts are optimal for general cognitive enhancement.
Is Alpha-GPC Safe for Long-Term Use?
Long-term safety remains uncertain. Short-term trials have reported generally manageable adverse events, while a large observational study found an association between Alpha-GPC exposure and increased stroke risk. That association does not establish causation, but it supports the need for further investigation.
Can Alpha-GPC Prevent Alzheimer's Disease?
There is insufficient evidence that Alpha-GPC prevents Alzheimer's disease or other forms of dementia. Studies involving people who already have cognitive impairment do not establish preventive effects in healthy populations.
Understanding Alpha-GPC: From Brain Chemistry to Informed Decisions
Alpha-GPC provides a useful example of both the potential and the limits of cognitive nutrition research.
Its relationship to choline metabolism is established, and choline's role in acetylcholine synthesis and cellular function is well understood.
Human trials have reported encouraging results in selected populations with cognitive impairment.
Yet important questions remain about benefits in healthy adults, meaningful long-term outcomes, comparative effectiveness, and safety.
For anyone researching Alpha-GPC, the most important distinction is between what the compound contributes to normal brain chemistry and what supplementation has actually been shown to accomplish.
Understanding that difference supports more informed decisions about cognitive wellness.
BioAdaptives' Human Renewal philosophy brings that scientific perspective into a broader view of human performance, cellular wellness, recovery, and healthy longevity.
Explore the Science of Human Renewal to learn how BioAdaptives approaches lifelong vitality through connected, evidence-informed wellness principles.
Scientific References
National Institutes of Health, Office of Dietary Supplements. Choline — Health Professional Fact Sheet. Established functions of choline, dietary sources, and nutritional requirements.
https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/De Jesus Moreno Moreno M. (2003). Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193.
https://doi.org/10.1016/S0149-2918(03)90023-3Fink HA, Hemmy LS, Linskens EJ, et al. (2020). Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia: A Systematic Review. Agency for Healthcare Research and Quality, Comparative Effectiveness Review No. 223.
https://www.ncbi.nlm.nih.gov/books/NBK556544/Jeon J, Lee SY, Lee S, et al. (2024). Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial. BMC Geriatrics, 24, Article 774.
https://doi.org/10.1186/s12877-024-05366-7Lee G, Choi S, Chang J, et al. (2021). Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Network Open, 4(11), e2136008.
https://doi.org/10.1001/jamanetworkopen.2021.36008JAMA Network Open. (2026). Errors in Methods and Article Information. Correction published September 24, 2026, addressing diagnostic-code descriptions and author information in the 2021 Alpha-GPC stroke-risk study.
https://doi.org/10.1001/jamanetworkopen.2026.39482
This article is intended for scientific education and general wellness information. It does not establish that Alpha-GPC or any BioAdaptives finished product prevents, treats, or reverses neurological disease or produces specific cognitive outcomes.